BIOMAT Database Logo BIOMAT Database Logo

[New looks in the treatment of haemophilia "A" patients with specific factor VIII inhibitors (author's transl)]. 1978

M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar

UI MeSH Term Description Entries
D008297 Male Males
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D005260 Female Females
D006467 Hemophilia A The classic hemophilia resulting from a deficiency of factor VIII. It is an inherited disorder of blood coagulation characterized by a permanent tendency to hemorrhage. Factor VIII Deficiency,Hemophilia,Autosomal Hemophilia A,Classic Hemophilia,Deficiency, Factor VIII,Factor 8 Deficiency, Congenital,Factor VIII Deficiency, Congenital,Haemophilia,Hemophilia A, Congenital,Hemophilia, Classic,As, Autosomal Hemophilia,Autosomal Hemophilia As,Classic Hemophilias,Congenital Hemophilia A,Congenital Hemophilia As,Hemophilia A, Autosomal,Hemophilia As,Hemophilia As, Autosomal,Hemophilia As, Congenital,Hemophilias, Classic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014812 Vitamin K A lipid cofactor that is required for normal blood clotting. Several forms of vitamin K have been identified: VITAMIN K 1 (phytomenadione) derived from plants, VITAMIN K 2 (menaquinone) from bacteria, and synthetic naphthoquinone provitamins, VITAMIN K 3 (menadione). Vitamin K 3 provitamins, after being alkylated in vivo, exhibit the antifibrinolytic activity of vitamin K. Green leafy vegetables, liver, cheese, butter, and egg yolk are good sources of vitamin K.

Related Publications

M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
[Emergency treatment of haemophilia A with factor VIII inhibitors using activated prothrombin complex concentrates (author's transl)].
March 1977, Deutsche medizinische Wochenschrift (1946),
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
May 2010, Haemophilia : the official journal of the World Federation of Hemophilia,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
[Treatment of haemophilia with factor VIII inhibitor by giving isoagglutinin-free factor VIII concentrate (author's transl)].
August 1976, Deutsche medizinische Wochenschrift (1946),
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
[Factor VIII inhibitor in a patient with mild haemophilia A (author's transl)].
December 1975, Haematologica,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Factor VIII inhibitors in haemophilia.
April 1983, Lancet (London, England),
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Pathophysiology of inhibitors to factor VIII in patients with haemophilia A.
May 2002, Haemophilia : the official journal of the World Federation of Hemophilia,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors.
May 2000, Haemophilia : the official journal of the World Federation of Hemophilia,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
The economic impact of factor VIII inhibitors in patients with haemophilia.
January 2004, Haemophilia : the official journal of the World Federation of Hemophilia,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
December 1997, Australian and New Zealand journal of medicine,
M Magallón Martínez, and F Ortega Blanco, and J Gago de Luis, and S Jover Sagarra, and J Martin Villar
Highly purified porcine factor VIII in haemophilia A with inhibitors to factor VIII.
January 1981, British medical journal (Clinical research ed.),
Copied contents to your clipboard!